Answers are grounded in this paper and cite their sources.
AI is increasingly integrated into reproductive medicine, particularly in in vitro fertilization (IVF) and embryology. This study presents a comparative analysis of two global surveys conducted among IVF specialists and embryologists in 2022 (n=383) and 2025 (n=171) to assess the adoption, application, and perceptions of AI-based tools. In 2022, 24.8% of respondents used AI, primarily for embryo selection (86.3% of AI users), with strong interest in AI for sperm selection (87.5%) and embryo annotation (92.4%). By 2025, AI usage increased to 53.22% (regular or occasional use, n=91), with 21.64% (n=37) reporting regular use and 31.58% (n=54) reporting occasional use, with embryo selection remaining the dominant application (32.75%). Familiarity with AI increased notably, with 60.82% reporting at least moderate familiarity in 2025, compared to indirect evidence of lower familiarity in 2022. Key barriers to adoption included cost (38.01%) and lack of training (33.92%) in 2025, while ethical concerns and over-reliance on technology were significant risks (59.06% cited over-reliance). Both surveys highlighted optimism for AI’s potential, with 91.6% (n=351) in 2022 and 38.6% (n=66) in 2025 identifying embryo selection as a key benefit of AI. Additionally, 83.62% (n=143) of 2025 respondents were likely to invest in AI within 1–5 years, indicating strong interest in future adoption. These findings suggest a gradual increase in AI adoption, tempered by practical and ethical challenges, with implications for training, cost management, and ethical frameworks in reproductive medicine.
No takes yet. Share an insight, caveat, or question.
Shoham et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: